Search

Displaying results 7151 - 7160 of 7452 in total
  1. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  2. Drug

    Lerdelimumab

    go.drugbank.com/drugs/DB06557
    Experimental

  3. Drug

    AM365

    go.drugbank.com/drugs/DB06564
    Experimental

    Detiviciclovir (AM365) is an antiviral nucleoside analogue.

  4. Drug

    Triphendiol

    go.drugbank.com/drugs/DB06588
    Experimental

  5. Drug

    Valtorcitabine

    go.drugbank.com/drugs/DB06187
    Investigational

  6. Drug

    Celgosivir

    go.drugbank.com/drugs/DB06580
    Investigational

  7. Drug

    Oregovomab

    go.drugbank.com/drugs/DB04964
    Investigational

    Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.

  8. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II s...

  9. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of hea...

  10. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.